

March 4, 2002

Aromatase Questions

1. Is the DRP complete and accurate? Does it form an adequate basis for making decisions about what prevalidation studies to initiate?
2. Do you agree with the recommendation to proceed with prevalidation studies on placental aromatase? Do you agree with the recommended protocol?
3. Do you agree with the DRP's conclusion that the disadvantages of cell based systems outweigh the advantages?
4. Do you agree with the recommendation to proceed with prevalidation studies on placental aromatase? Do you agree with the recommended protocol?
5. Do you agree that prevalidation studies should include optimization of concentrations of substrate, microsomal protein and co-factors? Is there any guidance you might provide regarding the design of such a study?
6. The DRP recommends an initial protocol demonstration of 1-3 chemicals. It recommends a short list of strong steroidal (4-hydroxyandrostenedione, exemestane, 7 α -substituted androstenedione) and non-steroidal inhibitors (aminoglutethimide, anastrole, letrozole). What chemicals should be selected for the initial demonstration?